A cute lymphoblastic leukemia (ALL) remains the most common malignancy in childhood. Asparaginase is a crucial component of ALL therapy and has proven efficacy in randomized trials when included with other chemotherapeutic agents. 1, 2 Asparaginase exhibits its antileukemic effect through hydrolyzation of the amino acid asparagine into aspartic acid and ammonia. Lymphoblasts lack the enzyme, asparagine synthetase, necessary to generate asparagine, resulting in a significant decrease in protein and nucleic acid synthesis within the cell. The end result of asparagine depletion in leukemic cells is a decrease in cell proliferation and the induction of apoptosis.
Harvested from Escherichia coli and Erwinia carotovora, L-asparaginase has gained solid footing in the treatment backbone for pediatric ALL. The inherent immunogenicity of this enzyme results in a number of undesirable side effects including hypersensitivity reactions and/or the development of antiasparaginase antibodies. Of particular concern is the development of silent antiasparaginase antibodies that can alter the activity and pharmacokinetics of asparaginase. [3] [4] [5] Although there is unease that the presence of such antibodies may impact outcomes, data to this effect are inconclusive. [6] [7] [8] Pharmacokinetic properties necessitating frequent administration coupled with an unfavorable side-effect profile led to the development of the polyethylene-glycolated (PEG) form of asparaginase. PEG-asparaginase (PEG-ASP) has a much longer half-life and less immunogenicity than native forms of the enzyme. 5, 9 Data suggest that having a previous hypersensitivity reaction to the native formulation will not have a relevant influence on the pharmacokinetics of PEG-ASP. 10 The majority of large clinical studies conducted in children have included only intramuscular (IM) PEG-ASP; intravenous (IV) administration has not been extensively evaluated. A previous study found a profound increased incidence of anaphylactic reactions after IV administration of native E. coli L-asparaginase when compared with IM routing of the same agent (23% vs. 0%) 11 ; no such data have been reported for PEG-ASP. Previous pediatric clinical trials do not suggest an increased risk of hypersensitivity reactions or other untoward side effects when using the IV route. [12] [13] [14] Despite the lack of pharmacokinetic and outcome data for IV PEG-ASP, the ease of administration and elimination of painful injections make the route appealing to patients, family, and nursing staff. We have begun to administer IV PEG-ASP with increasing frequency at our institution; we review our experience herein, particularly clinical hypersensitivity reactions. IV doses of PEG-ASP were administered over 60 minutes; institutional protocols for the monitoring of drug reactions were identical for IV and IM routing. All patients receiving IV PEG-ASP were either not eligible for or declined participation in Children's Oncology Group protocols, and the use of IV routing was at the discretion of the treating physician. PEG-ASP dosing intervals varied and the drug was frequently delivered concurrently with other chemotherapeutic agents. Reactions were identified from retrospective clinical chart review and graded according to the common toxicity criteria (CTCAE) set forth by the National Cancer Institute. Comparison analysis of the rate of hypersensitivity reactions between IV and IM routing was performed using the Fisher exact test and was based on cumulative exposures of each routing group as some patients had histories of both IM and IV PEG-ASP dosing.
MATERIALS AND METHODS

RESULTS
A total of 68 patients were available for evaluation during the study interval. Patient characteristics are outlined in Table 1 . The mean age of all patients was 7.7 years (range, 1.5 to 19 y). There were 16 patients who received IV PEG-ASP without prior exposure to IM administration. These patients received between 1 and 7 total doses of IV PEG-ASP (median: 2). The control group included 27 patients who received only IM PEG-ASP. The control patients received between 1 and 11 doses of IM PEG-ASP (median: 3). A third group of patients received a minimum of 1 dose of IM PEG-ASP, followed by IV PEG-ASP. This group includes 25 patients who received 2 to 12 total doses of PEG-ASP (median: 7). The entire cohort of 68 patients included primarily children with ALL (n = 61) with the remainder of patients being treated for acute myeloid leukemia (n = 3), non-Hodgkin lymphoma (n = 3), and Langerhans cell histiocytosis (n = 1).
A total of 7 hypersensitivity reactions were recorded in 68 patients (10.3%). All reactions were CTC grade 1 to 3, and no patient experienced anaphylaxis with either mode of administration. Two hypersensitivity reactions occurred in patients exposed only to IV PEG-ASP, after the second and fifth doses. Three reactions were seen in the control group, after IM PEG-ASP. These reactions occurred after the first, second, and third doses. There was no significant difference in the incidence of hypersensitivity reactions between the 2 groups (cases: 12.5%, controls: 11.1%, P = not significant). In the group exposed to both IV and IM formulations, 1 patient experienced a hypersensitivity reaction after the seventh IV dose, after initially receiving treatment with a single dose of IM PEG-ASP, and a second patient had a reaction after the sixth IV dose after initially receiving a single IM dose. In patients who experienced a hypersensitivity reaction, the reaction occurred after 1 to 8 total doses of PEG-ASP (median: 3 doses). Patients who reacted to IV PEG-ASP were exposed to more prior doses of asparaginase than those who reacted to IM dosing (median: 6 vs. 2). Patients who experienced hypersensitivity reactions to PEG-ASP along with the number of doses received and route of administration are outlined in Table 2 . During the study period, 2 patients who experienced a reaction to IM PEG-ASP were subsequently treated with PEG-ASP using IV administration. Both resulted in a recurrence of hypersensitivity with the first dose.
In the entire cohort, 215 doses of IM PEG-ASP were administered to 52 patients. The median number of IM doses per patient was 3 (range, 1 to 11). There were 3 documented allergic reactions after IM PEG-ASP doses (1.4%), including 1 severe (grade 3 or 4) reaction (0.5%). There were 119 doses of IV PEG-ASP administered to 41 patients. The median number of IV doses per patient was 2 (range, 1 to 7). Multiple doses of IV PEG-ASP were administered to 28 patients. There were 4 documented allergic reactions in patients after IV PEG-ASP doses (3.4%), including 1 severe reaction (0.8%). Two patients who reacted to IV PEG-ASP had previously been exposed to IM PEG-ASP, whereas 2 patients had received only IV doses of PEG-ASP. The rate of total and severe hypersensitivity reactions was not significantly different between the 2 groups (Table 3) . On a per dose basis, IV PEGasparaginase was associated with a nonsignificant increase in the incidence of allergic reactions (odds ratio 2.5; 95% confidence interval, 0.6-11.4).
Other adverse reactions to PEG-ASP included 4 episodes of pancreatitis, 2 of which occurred in the IM PEG-ASP group and 2 occurred in the IV PEG-ASP group. There was also 1 episode of thrombosis thought to be related to PEG-ASP that occurred in the IM PEG-ASP group.
DISCUSSION
Asparaginase is a critical component of multiagent therapy in pediatric ALL. Clinical trials have demonstrated that optimal administration of asparaginase improves outcomes. 1,2,4,9,15-18 Hypersensitivity reactions are not infrequent after the administration of asparaginase, and their occurrence necessitates changing the formulation of asparaginase or discontinuing therapy. It is therefore imperative that these reactions be minimized during treatment, as their occurrence may have adverse effects on outcomes. Factors that may influence the incidence of these 9 The evaluation of IV PEG-ASP in children is limited, and more extensive evaluation of its pharmacokinetics and impact on outcomes is essential.
Our results indicate that IV PEG-ASP results in a relatively low incidence of hypersensitivity reactions that is comparable to that seen with the use of IM PEG-ASP. Previous studies have evaluated the use of a solitary dose of IV PEG-ASP in children and found a low incidence of reactions. A single 500 IU/m 2 dose of IV PEG-ASP was administered to patients with relapsed ALL treated on BFM 96 and 5 of 28 patients (17.9%) had a subsequent severe allergic reaction. 9, 10 Muller reported on 70 newly diagnosed patients with ALL or lymphoma who received one 1000 IU/m 2 dose of IV PEG-ASP during induction without any reactions. 9, 13 In 59 patients enrolled on BFM trials who received a 2500 IU/m 2 dose of IV PEG-ASP, there was no incidence of hypersensitivity reactions. 12 Our patient population is unique from these studies as the majority of patients were exposed to multiple doses of IM and/or IV PEG-ASP, and therefore were more likely to experience a reaction. It is also worth noting that patients in our study are heterogenous and were being treated with a variety of chemotherapy combinations along with PEG-ASP, which may impact the incidence of allergic reactions. 19, 20 The IV administration of PEG-ASP is preferred by patients and staff as it eliminates painful injections and reduces patient anxiety. IV administration also allows for early discontinuation of the infusion at the first sign of allergy, a practice that may limit the severity of reactions.
It has been demonstrated that effective serum asparagine depletion can be achieved after IV administration. 14, [22] [23] [24] The administration of IV PEG-ASP results in more rapid depletion of asparagine than is seen after IM dosing, which may portend additional clinical benefits. In adults, the administration of a single IV dose of 2000 IU/m 2 of PEG-ASP resulted in complete depletion of asparagine 2 hours after administration that persisted for >14 days in all 25 patients. 22 The Dana Farber Cancer Institute ALL Consortium Protocol 05-01 randomized patients to receive IV PEG-ASP every 2 weeks or IM Lasparginase weekly during the 30-week continuation phase of therapy. 24 Asparagine depletion was more pronounced in the IV PEG-ASP group at all time points, and toxicities were equal between the 2 groups. Follow-up on this protocol is not long enough to determine whether this will correlate with improved outcomes in the IV PEG-ASP group.
In our study, the patients exposed to only IM or only IV PEG-ASP had similar rates of hypersensitivity reactions. When patients who received PEG-ASP by both routes were included, we noted a nonsignificant increase in hypersensitivity reactions after the IV administration of PEG-ASP on a per dose basis. As this study was retrospective, this is likely confounded as patients who reacted to IV PEG-ASP tended to have more total asparaginase exposures, resulting in an increased likelihood of experiencing a reaction. 25 Further comparison of the 2 routes of administration in a controlled study is necessary before we can determine whether the administration of IV PEG-ASP results in a difference in the rate of hypersensitivity reactions compared with native L-asparaginase.
The presence of hypersensitivity reactions in patients who receive asparaginase is associated with the production of antiasparaginase antibodies and decreased asparaginase activity. 3, 5, 26 The incidence of antibody formation after asparaginase is variable, but rates as high as 61% have been reported in children with high-risk ALL. 6, 8 In some studies, developing antiasparaginase antibodies has been associated with decreased asparaginase activity and poor outcomes. 6, 20, 27 Other studies have not found an association between survival and either hypersensitivity reactions or the presence of antibodies. 8, [28] [29] [30] It remains unclear whether the formation of antibodies to asparaginase effects outcomes in children with ALL. When administered IM, PEG-ASP has resulted in a significant reduction in antibody formation when compared with other forms of asparaginase. 9 It is not known whether administering PEG-ASP IV has an impact on the immunogenicity of the protein.
Our findings, although limited by the small number of patients, do not suggest an increase in the other side effects of asparaginase including pancreatitis and thrombosis when PEG-ASP is administered IV. Other studies of IV PEG-ASP in children do not demonstrate an increase in the occurrence of these or other asparaginase-related side effects. 9, 10, 13, 14 It remains a possibility that the unique pharmacokinetic profile of IV PEG-ASP may contribute to 2  4  3  0  IM  2  7  4  1  6  IV  2  12  11  0  5  IV  2  26  14  2  0  IM  2  33  19  1  0  IM  3  52  10  1  7  IV  1  56  6  0  2  IV  3 IM indicates intramuscular; IV, intravenous; PEG-ASP, polyethyleneglycol-asparginase. a slight difference in the incidence of other nonhypersensitivity toxicities. On the basis of these results and the results of other studies, it seems that the IV dosing of PEG-ASP is an acceptable alternative to IM dosing. Further evaluation is warranted, to ensure that IV dosing does not adversely impact outcomes in pediatric ALL, either by preventing optimal administration of asparaginase through an increase in hypersensitivity reactions or through the formation of silent antiasparaginase antibodies. Ideally, these studies would include measurement of asparagine depletion after PEG-ASP administration and an evaluation of the rate of antiasparaginase antibody formation.
